Merrion completes clinical study

MERRION PHARMACEUTICALS yesterday announced the successful completion of a clinical study of MER 103, which increases drug absorption.

The study confirmed important improvements for patient convenience and compliance relating to the administration of alendronate.

Merrion chief executive Michael McKenna said: “Merrion’s improvements in this therapy constitute a significant advance. We look forward to discussing these results and the further clinical development of MER 103 with prospective collaborators.”